Discovery of Novel Inhibitors of the FKBP51 Protein from a High-throughput Drug Screen
- Technology Benefits
- First treatment to target FKBP51, All FDA approved compounds, Can be immediately implemented
- Detailed Technology Description
- Through the use of high-throughput screening University of South Florida researchers have identified several compounds with strong inhibitory activity against FKBP51, which could potentially be immediately implemented into clinics to treat specific patient populations with high levels of FKBP51. These drugs are all FDA approved and could be prescribed off label for the purpose of reducing FKBP51 levels. Patients with elevated levels of FKBP51, specifically those with SNPs in the FKBP5 gene or aged/AD patients, could immediately benefit from receiving drugs that target inhibition of FKBP51.
- *Abstract
-
Researchers at the University of South Florida have identified several compoundsthat act as inhibitors against the FKBP51 protein, which may provide a treatment for major depression, post-traumatic stress disorder (PTSD), anxiety disorders, and AlzheimerΓÇÖs disease.
- Country/Region
- USA
For more information, please click Here
